Seeking Alpha

Pfizer buys Baxter's vaccine business

  • Pfizer (PFE -1.7%) enters into a definitive agreement to acquire Baxter International's (BAX +0.7%) vaccine business for $635M. The transaction includes a portion of Baxter's manufacturing facility in Orth, Austria.
  • The deal is expected to close by the end of 2014. Pfizer says that it will not impact its guidance for the year.
From other sites
Comments (5)
  • Dividend Growth Jedi
    , contributor
    Comments (347) | Send Message
     
    Hmm. Makes sense for pfe as the 2 vacvines will compliment their vaccine portfolio. Wasnt expecting bax to make any sales prespinoff. Hopefully they use this cash to pay down some debt.
    30 Jul 2014, 10:04 AM Reply Like
  • bexpo
    , contributor
    Comments (201) | Send Message
     
    Why is this negatively affecting the stock?
    30 Jul 2014, 03:32 PM Reply Like
  • Dividend Growth Jedi
    , contributor
    Comments (347) | Send Message
     
    Are you referring to PFE or BAX. Both seem to be just normal market behavior. Although I think for PFE is pulling back last few days for earnings reasons (lowered guidance) and the fact that they seem intent on doing some type of large tax inversion acquisition instead of focusing on products.
    30 Jul 2014, 06:53 PM Reply Like
  • bexpo
    , contributor
    Comments (201) | Send Message
     
    I was referring to BAX? Was it negative for BAX to sell off that division?
    31 Jul 2014, 04:13 PM Reply Like
  • michael531
    , contributor
    Comments (6) | Send Message
     
    ok
    30 Jul 2014, 11:46 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs